CO2019007321A2 - Derivados de pirano como inhibidores de cyp11a1 (citocromo p450 monooxigenasa 11a1) - Google Patents
Derivados de pirano como inhibidores de cyp11a1 (citocromo p450 monooxigenasa 11a1)Info
- Publication number
- CO2019007321A2 CO2019007321A2 CONC2019/0007321A CO2019007321A CO2019007321A2 CO 2019007321 A2 CO2019007321 A2 CO 2019007321A2 CO 2019007321 A CO2019007321 A CO 2019007321A CO 2019007321 A2 CO2019007321 A2 CO 2019007321A2
- Authority
- CO
- Colombia
- Prior art keywords
- cyp11a1
- monooxygenase
- cytochrome
- inhibitors
- compounds
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
- C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/056—Ortho-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pyrane Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FI20166024 | 2016-12-22 | ||
| PCT/FI2017/050926 WO2018115591A1 (en) | 2016-12-22 | 2017-12-21 | Pyran dervatives as cyp11a1 (cytochrome p450 monooxygenase 11a1) inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO2019007321A2 true CO2019007321A2 (es) | 2019-07-31 |
Family
ID=61005837
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CONC2019/0007321A CO2019007321A2 (es) | 2016-12-22 | 2019-07-09 | Derivados de pirano como inhibidores de cyp11a1 (citocromo p450 monooxigenasa 11a1) |
Country Status (31)
| Country | Link |
|---|---|
| US (4) | US10717726B2 (enExample) |
| EP (2) | EP3558981B1 (enExample) |
| JP (2) | JP7025432B2 (enExample) |
| KR (3) | KR20250097993A (enExample) |
| CN (2) | CN116162084B (enExample) |
| AR (1) | AR110412A1 (enExample) |
| AU (2) | AU2017380282B2 (enExample) |
| CA (1) | CA3047370A1 (enExample) |
| CL (1) | CL2019001728A1 (enExample) |
| CO (1) | CO2019007321A2 (enExample) |
| CY (1) | CY1124461T1 (enExample) |
| DK (1) | DK3558981T3 (enExample) |
| EA (1) | EA039309B1 (enExample) |
| ES (1) | ES2880151T3 (enExample) |
| HR (1) | HRP20211255T1 (enExample) |
| HU (1) | HUE056540T2 (enExample) |
| IL (2) | IL267484B (enExample) |
| LT (1) | LT3558981T (enExample) |
| MA (2) | MA55983A (enExample) |
| MX (1) | MX388538B (enExample) |
| NZ (1) | NZ755395A (enExample) |
| PE (1) | PE20191137A1 (enExample) |
| PH (1) | PH12019550111A1 (enExample) |
| PL (1) | PL3558981T3 (enExample) |
| PT (1) | PT3558981T (enExample) |
| RS (1) | RS62198B1 (enExample) |
| SI (1) | SI3558981T1 (enExample) |
| TN (1) | TN2019000189A1 (enExample) |
| TW (2) | TWI796205B (enExample) |
| UA (1) | UA124640C2 (enExample) |
| WO (1) | WO2018115591A1 (enExample) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR110412A1 (es) * | 2016-12-22 | 2019-03-27 | Orion Corp | Inhibidores de la cyp11a1 |
| CN115551831A (zh) | 2020-05-14 | 2022-12-30 | 奥赖恩公司 | Cyp11a1抑制剂 |
| JP2023551340A (ja) * | 2020-12-01 | 2023-12-07 | オリオン コーポレーション | 前立腺がんの治療のためのｃｙｐ１１ａ１阻害薬としての２，３－ジヒドロ－４ｈ－ベンゾ［ｂ］［１，４］オキサジン－４－イル）（５－（フェニル）－ピリジン－３－イル）メタノン誘導体および類似化合物 |
| PE20231939A1 (es) * | 2021-03-01 | 2023-12-05 | Orion Corp | Proceso para la preparacion de un inhibidor de cyp11a1 y sus intermedios |
| KR20230165774A (ko) | 2021-03-01 | 2023-12-05 | 오리온 코포레이션 | 4h-피란-4-온 구조의 cyp11a1 억제제의 고체 형태 |
| AR124985A1 (es) | 2021-03-01 | 2023-05-24 | Orion Corp | Nuevas formas de sal de un inhibidor de cyp11a1 estructurado en 4h-piran-4-ona |
| JP2024526159A (ja) | 2021-06-23 | 2024-07-17 | オリオン・コーポレーション | Ｃｙｐ１１ａ１阻害薬及びその中間体を調製する方法 |
| EP4408426A1 (en) * | 2021-09-28 | 2024-08-07 | Orion Corporation | Cyp11a1 inhibitor for use in the treatment of prostate cancer |
| US20250257054A1 (en) | 2021-10-28 | 2025-08-14 | Orion Corporation | Salt forms of a 4h-pyran-4-one structured cyp11 a1 inhibitor |
| EP4430027A1 (en) | 2021-11-10 | 2024-09-18 | Orion Corporation | Cyp11a1 inhibitors |
| CN118695853A (zh) | 2022-01-20 | 2024-09-24 | 奥仁公司 | Cyp11a1抑制剂的药物组合物 |
| JP7645296B2 (ja) * | 2022-02-08 | 2025-03-13 | ディーエヌエフ カンパニー リミテッド | ヨウ素含有金属化合物およびこれを含む薄膜蒸着用組成物 |
| CN118307519A (zh) | 2023-01-06 | 2024-07-09 | 上海闻耐医药科技有限公司 | 一类cyp11a1抑制剂化合物及其制备方法和用途 |
| KR20240126916A (ko) | 2023-02-14 | 2024-08-22 | 경북대학교 산학협력단 | Asm 단백질 또는 이의 단편을 포함하는 퇴행성 신경질환 또는 우울증 예방 또는 치료용 조성물 |
| AU2024242063A1 (en) | 2023-03-29 | 2025-10-09 | Xizang Haisco Pharmaceutical Co., Ltd. | Cyp11a1 inhibitor and use thereof |
| CN121039123A (zh) | 2023-04-21 | 2025-11-28 | 西藏海思科制药有限公司 | Cyp11a1抑制剂及其用途 |
| AU2024270498A1 (en) * | 2023-05-11 | 2025-11-27 | Foshan Ionova Biotherapeutics Co., Inc. | Novel compounds as cyp11a1 inhibitors and methods of use thereof |
| WO2025017072A1 (en) | 2023-07-19 | 2025-01-23 | Orion Corporation | Stable pharmaceutical compositions of a cyp11a1 inhibitor |
| WO2025021182A1 (en) * | 2023-07-27 | 2025-01-30 | Acerand Therapeutics (Hong Kong) Limited | Cyp11a1 inhibitors |
| WO2025051216A1 (zh) * | 2023-09-08 | 2025-03-13 | 深圳众格生物科技有限公司 | 一种cyp11a1抑制剂、其制备方法及其应用 |
| WO2025168117A1 (zh) * | 2024-02-08 | 2025-08-14 | 盛睿泽华医药科技（苏州）有限公司 | 一种多环化合物及其制备方法和应用 |
| WO2025237211A1 (zh) * | 2024-05-11 | 2025-11-20 | 辽宁海思科制药有限公司 | 一种cyp11a1抑制剂的晶型物及其制备方法和应用 |
| WO2025247149A1 (zh) * | 2024-05-27 | 2025-12-04 | 辽宁海思科制药有限公司 | 一种cyp11a1抑制剂的盐及其晶型、其制备方法和应用 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS6176485A (ja) * | 1984-09-20 | 1986-04-18 | Ss Pharmaceut Co Ltd | 新規なγ−ピラン誘導体 |
| AU2003217304A1 (en) * | 2002-02-28 | 2003-09-16 | The University Of Tennessee Research Corporation | Radiolabeled selective androgen receptor modulators and their use in prostate cancer imaging and therapy |
| EP1471063A1 (en) * | 2003-02-28 | 2004-10-27 | Exonhit Therapeutics S.A. | Compounds and methods of treating cell proliferative diseases, retinopathies and arthritis |
| US20140005181A1 (en) * | 2012-06-21 | 2014-01-02 | Sanford-Burnham Medical Research Institute | Small molecule antagonists of the apelin receptor for the treatment of disease |
| TW201534586A (zh) * | 2013-06-11 | 2015-09-16 | Orion Corp | 新穎ｃｙｐ１７抑制劑／抗雄激素劑 |
| AR110412A1 (es) * | 2016-12-22 | 2019-03-27 | Orion Corp | Inhibidores de la cyp11a1 |
-
2017
- 2017-12-20 AR ARP170103609A patent/AR110412A1/es active IP Right Grant
- 2017-12-21 ES ES17832250T patent/ES2880151T3/es active Active
- 2017-12-21 PE PE2019001297A patent/PE20191137A1/es unknown
- 2017-12-21 TN TNP/2019/000189A patent/TN2019000189A1/en unknown
- 2017-12-21 UA UAA201908272A patent/UA124640C2/uk unknown
- 2017-12-21 LT LTEP17832250.9T patent/LT3558981T/lt unknown
- 2017-12-21 EP EP17832250.9A patent/EP3558981B1/en active Active
- 2017-12-21 EA EA201991513A patent/EA039309B1/ru unknown
- 2017-12-21 MA MA055983A patent/MA55983A/fr unknown
- 2017-12-21 HR HRP20211255TT patent/HRP20211255T1/hr unknown
- 2017-12-21 TW TW111114824A patent/TWI796205B/zh active
- 2017-12-21 MA MA47102A patent/MA47102B1/fr unknown
- 2017-12-21 KR KR1020257020993A patent/KR20250097993A/ko active Pending
- 2017-12-21 PL PL17832250T patent/PL3558981T3/pl unknown
- 2017-12-21 CA CA3047370A patent/CA3047370A1/en active Pending
- 2017-12-21 HU HUE17832250A patent/HUE056540T2/hu unknown
- 2017-12-21 RS RS20210994A patent/RS62198B1/sr unknown
- 2017-12-21 WO PCT/FI2017/050926 patent/WO2018115591A1/en not_active Ceased
- 2017-12-21 KR KR1020197021256A patent/KR102491308B1/ko active Active
- 2017-12-21 TW TW106145006A patent/TWI762544B/zh active
- 2017-12-21 AU AU2017380282A patent/AU2017380282B2/en active Active
- 2017-12-21 JP JP2019534192A patent/JP7025432B2/ja active Active
- 2017-12-21 DK DK17832250.9T patent/DK3558981T3/da active
- 2017-12-21 EP EP21165964.4A patent/EP3868756A1/en not_active Withdrawn
- 2017-12-21 SI SI201730841T patent/SI3558981T1/sl unknown
- 2017-12-21 MX MX2019007373A patent/MX388538B/es unknown
- 2017-12-21 PT PT178322509T patent/PT3558981T/pt unknown
- 2017-12-21 KR KR1020237002074A patent/KR102826021B1/ko active Active
- 2017-12-21 US US16/472,377 patent/US10717726B2/en active Active
- 2017-12-21 CN CN202211597796.4A patent/CN116162084B/zh active Active
- 2017-12-21 NZ NZ755395A patent/NZ755395A/en unknown
- 2017-12-21 CN CN201780079479.4A patent/CN110139861B/zh active Active
-
2019
- 2019-06-19 IL IL267484A patent/IL267484B/en unknown
- 2019-06-20 CL CL2019001728A patent/CL2019001728A1/es unknown
- 2019-06-21 PH PH12019550111A patent/PH12019550111A1/en unknown
- 2019-07-09 CO CONC2019/0007321A patent/CO2019007321A2/es unknown
-
2020
- 2020-06-08 US US16/895,221 patent/US11098032B2/en active Active
-
2021
- 2021-05-28 AU AU2021203497A patent/AU2021203497B2/en active Active
- 2021-07-06 US US17/367,849 patent/US12030871B2/en active Active
- 2021-08-19 IL IL285729A patent/IL285729B/en unknown
- 2021-08-25 CY CY20211100760T patent/CY1124461T1/el unknown
-
2022
- 2022-02-10 JP JP2022019891A patent/JP7286825B2/ja active Active
-
2024
- 2024-05-24 US US18/674,603 patent/US20240308989A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2019007321A2 (es) | Derivados de pirano como inhibidores de cyp11a1 (citocromo p450 monooxigenasa 11a1) | |
| MX2023001876A (es) | Derivados de rapamicina. | |
| ECSP20033467A (es) | Compuestos macrocíclicos para tratar enfermedades | |
| MX2019008698A (es) | Derivado de piridina como inhibidor de ask1 y metodo de preparacion y uso del mismo. | |
| CO2017002191A2 (es) | Inhibidores de desmetilasa-1 específica a lisina | |
| CO2017000362A2 (es) | Compuestos de derivados heterocíclicos sustituidos como inhibidores de demtilasa-1 específica lisina | |
| MX2017000450A (es) | Compuestos terapeuticos inhibidores. | |
| MX2019003143A (es) | Compuesto heterociclico sustituido con alquinilo, su metodo de preparacion y su uso medico. | |
| CL2015002520A1 (es) | Compuestos novedosos de pirimidina y piridina y su uso. | |
| PH12015502525A1 (en) | Ester derivatives of androgen receptor modulators and methods for their use | |
| ECSP18003372A (es) | Compuestos tricíclicos y su uso como inhibidores de la fosfodiesterasa | |
| SV2017005381A (es) | Compuestos de imidazopiridazina | |
| DOP2019000100A (es) | Derivados de naftiridinona y su uso en el tratamiento de la arritmia | |
| CO2017000011A2 (es) | Derivados de quinolizinona como inhibidores de pi3k | |
| CO2020010306A2 (es) | Compuestos de sulfonimidoilpurinona 7-sustituida y derivados para el tratamiento y profilaxis de cáncer de hígado. | |
| CL2018003610A1 (es) | Nuevos derivados de [1,2,3]triazolo[4,5-d]pirimidina. | |
| MX388654B (es) | Derivados de cromano y uso de los mismos en el tratamiento de daño en un órgano diabético, tal como un riñón. | |
| GT201600232A (es) | Derivados de diheterociclo enlazado a cicloalquilo | |
| CR20150148A (es) | Azaindolinas | |
| UY36132A (es) | Métodos para terapia de cáncer | |
| TR201813294T4 (tr) | N-aril-2-amino-4-aril-pirimidin makrosi̇kli̇k poli̇eter türevleri̇ ve bunlarin flt3 ve jak i̇nhi̇bi̇törleri̇ olarak kullanimlari. | |
| CL2018002347A1 (es) | Nuevos derivados pirrolidina | |
| CU20120067A7 (es) | Derivados de sulfamida heterocíclicos y su uso como inhibidores de mek |